Evaluation of new or repurposed treatments for COVID-19: protocol for the phase Ib/IIa DEFINE trial platform
COVID-19에 대한 신규 또는 용도 변경 치료제 평가: Ib/IIa상 DEFINE 시험 플랫폼 프로토콜
Article
[키워드] acceptance
adaptive
administration
Analysis
Appropriate
approval
Arm
ARMS
assisted ventilation
caused
changes in
clinical trial
Coagulation
Cohort
Community
Complete
computer
COVID-19
COVID-19 therapy
dependent on
development
during treatment
effective
Efficacy
Ethics
ethics committee
EudraCT
Evidence
evidence of
Experimental medicine
exploratory
Follow-up
hospital
Hospital stay
hospitalised patient
Infection
Infectious diseases
information
initial
mechanism
mechanism of action
Medicine
MHRA
National Health Service
NEWS2
NHS
Novel coronavirus
Open-label
Ordinal Scale
oxygen
Oxygen requirements
participant
Pathways
Patient
patient cohorts
patient safety
patients with COVID-19
peer-reviewed
pharmacokinetic
Pneumonia
Pneumonitis
positive
present
product
protocol
randomisation
randomised
Randomised Evaluation
REC
recovery
recruited
recruitment
registration number
research and development
Research Ethics
Research Ethics Committee
respiratory medicine (see thoracic medicine)
Safe
SARS-CoV-2
score
secondary
Standard of care
statistical analysis
submitted
Support
Therapeutics
Therapeutics.
therapy
Thoracic
Treatment
treatment arm
treatment period
Trial
trial platform
variable
Viral load
viral-induced
WHO ordinal scale
[DOI] 10.1136/bmjopen-2021-054442 PMC 바로가기 [Article Type] Article
[DOI] 10.1136/bmjopen-2021-054442 PMC 바로가기 [Article Type] Article